2016-2018年美国商业保险与医疗补助保险孕妇疫苗接种暴露研究
本研究基于2016年8月至2018年12月IBM MarketScan商业、BHI商业及MarketScan多州Medicaid数据库的回顾性队列,纳入年龄12-55岁、结局为活产、自然流产或死胎的妊娠。结果显示,三个数据库中Tdap接种率分别为52.1%、50.3%、31.3%,流感疫苗为32.1%、30.8%、18.0%,而HPV接种<0.2%、MMR<0.1%。结论:推荐疫苗接种率不理想,Medicaid参保者更低,禁忌疫苗意外暴露罕见。
要点
- 商业保险孕妇Tdap接种率约50%,Medicaid约31%,均未达理想水平。
- 流感疫苗接种率商业保险约30-32%,Medicaid约18%。
- HPV和MMR等不推荐/禁忌疫苗孕期暴露率均低于0.2%。
核心结论
- ACIP推荐疫苗在商业保险和Medicaid参保孕妇中接种率均不理想,Medicaid参保者更低。
- 孕期意外暴露于禁忌疫苗(如MMR、水痘、减毒流感)罕见。
研究设计与样本
- 回顾性队列研究,数据来自IBM MarketScan商业、BHI商业和MarketScan多州Medicaid数据库,2016年8月1日至2018年12月31日。
- 纳入年龄12-55岁、妊娠结局为活产、自然流产或死胎的孕妇,共识别496,771例(MarketScan商业)、858,961例(BHI)、289,573例(MarketScan Medicaid),约75%年龄20-34岁。
- 使用验证算法确定接种时的孕周。
主要发现
- Tdap接种率:MarketScan商业52.1%、BHI 50.3%、Medicaid 31.3%,接种孕周最常见为28周。
- 流感疫苗接种率:MarketScan商业32.1%、BHI 30.8%、Medicaid 18.0%。
- HPV疫苗接种率<0.2%,多见于12-19岁女性孕早期;MMR接种率<0.1%。
- 其他ACIP禁忌疫苗(如水痘、减毒流感)使用罕见。
临床怎么用
- 应加强孕期ACIP推荐疫苗(Tdap和流感)的接种,尤其关注Medicaid参保人群。
- 孕期接种前应评估疫苗禁忌,避免意外暴露于MMR、HPV等不推荐或禁忌疫苗。
局限性
- 仅评估有保险人群中已报销的疫苗接种,可能无法推广至无保险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine use during pregnancy affects maternal and infant health. Many women do not receive vaccines recommended during pregnancy; conversely, inadvertent exposure to vaccines contraindicated or not recommended during pregnancy may occur. We assessed exposure to two recommended vaccines and two vaccines not recommended during pregnancy among privately and Medicaid-insured women in the United States. METHODS: This study includes a retrospective cohort of pregnancies in women aged 12-55 years resulting in live birth, spontaneous abortion, or stillbirth identified in the IBM® MarketScan® Commercial, Blue Health Intelligence® (BHI®) Commercial, and IBM MarketScan Multi-State Medicaid Databases from August 1, 2016, to December 31, 2018. Gestational age at vaccination was determined using a validated algorithm. We examined vaccines (1) recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) (tetanus, diphtheria, and acellular pertussis [Tdap]; inactivated influenza) and (2) not recommended (human papillomavirus [HPV]) or contraindicated (measles, mumps, and rubella [MMR]). RESULTS: We identified 496,771 (MarketScan Commercial), 858,961 (BHI), and 289,573 (MarketScan Medicaid) pregnancies (approximately 75% aged 20-34 years). Across these three databases, 52.1%, 50.3%, and 31.3% of pregnancies, respectively, received Tdap, most often at a gestational age of 28 weeks, and influenza vaccination occurred in 32.1%, 30.8%, and 18.0% of pregnancies, respectively. HPV vaccination occurred in < 0.2% of pregnancies, mostly in the first trimester among women aged 12-19 years, and MMR was administered in < 0.1% of pregnancies. Use of other contraindicated vaccines per ACIP (e.g., varicella, live attenuated influenza) was rare. CONCLUSION: Maternal vaccination with ACIP-recommended vaccines was suboptimal among privately and Medicaid-insured patients, with lower vaccination coverage among Medicaid-insured pregnancies than their privately insured counterparts. Inadvertent exposure to contraindicated vaccines during pregnancy was rare. This study evaluated only vaccinations reimbursed among insured populations and may have limited generalizability to uninsured populations.
引用
- Moll K, Wong HL, Fingar K, et al. Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016-2018. Vaccine. 2021. PMID: 34507857. doi:10.1016/j.vaccine.2021.08.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。